{"protocolSection":{"identificationModule":{"nctId":"NCT00836498","orgStudyIdInfo":{"id":"V260-027"},"secondaryIdInfos":[{"id":"2007_537"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)","officialTitle":"V260-027 Safety and Immunogenicity of RotaTeq™ in Elderly Subjects"},"statusModule":{"statusVerifiedDate":"2015-04","overallStatus":"TERMINATED","whyStopped":"Strategic business decision not to pursue indication due to lack of demonstrable medical need","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-01"},"primaryCompletionDateStruct":{"date":"2010-01","type":"ACTUAL"},"completionDateStruct":{"date":"2010-01","type":"ACTUAL"},"studyFirstSubmitDate":"2009-02-03","studyFirstSubmitQcDate":"2009-02-03","studyFirstPostDateStruct":{"date":"2009-02-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-01-12","resultsFirstSubmitQcDate":"2011-01-12","resultsFirstPostDateStruct":{"date":"2011-02-04","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-04-10","lastUpdatePostDateStruct":{"date":"2015-05-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is a Phase I clinical trial including 2 parts to evaluate the safety and immune response to RotaTeq™ /placebo in subjects of 65 to 80 years of age. In Part I, approximately 60 subjects in US will be randomly assigned to 1 of 2 treatment groups receiving 3 doses of RotaTeq™ or placebo. In Part II, approximately 200 subjects internationally will be randomly assigned to 1 of 3 treatment groups. Part II will start after Part I data analysis is reviewed and approved by the FDA/CBER, the Safety Evaluation Committee (SEC) and other regulatory agencies. Duration for the entire study will be approximately 4 years.\n\nNote: As the result of a business decision by the Sponsor, the study did not proceed with Part II. Therefore, this report includes the results for Part I only."},"conditionsModule":{"conditions":["Rotavirus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":66,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part I, RotaTeq","type":"EXPERIMENTAL","description":"3 doses of RotaTeq","interventionNames":["Biological: Comparator: RotaTeq"]},{"label":"Part I, placebo","type":"PLACEBO_COMPARATOR","description":"3 doses of placebo","interventionNames":["Biological: Comparator: Placebo"]},{"label":"Part II, RotaTeq","type":"EXPERIMENTAL","description":"3 doses of RotaTeq","interventionNames":["Biological: Comparator: RotaTeq"]},{"label":"Part II, RotaTeq and placebo","type":"EXPERIMENTAL","description":"1 dose of RotaTeq and 2 doses of placebo","interventionNames":["Biological: Comparator: RotaTeq + Placebo"]},{"label":"Part II, placebo","type":"PLACEBO_COMPARATOR","description":"3 doses of placebo","interventionNames":["Biological: Comparator: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Comparator: RotaTeq","description":"Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.","armGroupLabels":["Part I, RotaTeq","Part II, RotaTeq"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","description":"Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.","armGroupLabels":["Part I, placebo","Part II, placebo"]},{"type":"BIOLOGICAL","name":"Comparator: RotaTeq + Placebo","description":"One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period","armGroupLabels":["Part II, RotaTeq and placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part I: Number of Participants With Nonserious and Serious Adverse Experiences (AEs)","description":"All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.","timeFrame":"Up to 42 days following any dose of RotaTeq™ or placebo"},{"measure":"Part I: Number of Participants With Serious Adverse Experiences (SAEs)","description":"All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.\n\nSAEs were followed by passive surveillance (in which either participants self reported or information was collected at participants' last visit) for 180 days following the final dose.","timeFrame":"Up to 180 days following the third dose of RotaTeq™ or placebo"},{"measure":"Part I: Geometric Mean Titers (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)","description":"GMTs of serum anti-rotavirus IgA responses after 1, 2, or 3 doses of RotaTeq™ or placebo.","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo"},{"measure":"Part II: Number of Participants With Nonserious Adverse Experiences","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","timeFrame":"Up to 42 days following any dose of RotaTeq™ and/or placebo"},{"measure":"Part II: Number of Participants With Serious Adverse Experiences","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","timeFrame":"Up to 180 days following the third dose of RotaTeq™ and/or placebo"},{"measure":"Part II: Geometric Mean Titer (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3"}],"secondaryOutcomes":[{"measure":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G1","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo"},{"measure":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G2","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo"},{"measure":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G3","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo"},{"measure":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G4","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo"},{"measure":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype P1A[8]","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo"},{"measure":"Part II: Geometric Mean Titers (GMTs) of Serum Neutralizing Antibody (SNA) Responses to G1, G2, G3, G4, and P1A","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3"},{"measure":"Part II: Percentage of Participants With a >=3-fold Rise From Baseline of Serum Anti-rotavirus IgA and SNA Responses to Rotavirus Serotypes G1, G2, G3, G4 and P1A","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is 65 to 80 years of age with controlled chronic illness\n* agrees to participate in the study by giving written informed consent and cognitively competent as assessed by Mini-Mental State Examination\n* for Part I: subject is living independently outside any long-term care facilities; for Part II: subject is expected to be a resident in a long term care facility (LTCF) including nursing homes with the exception of hospice care\n* can be adequately followed for safety via visit or phone\n* subject's routine safety lab results are within specified ranges\n* has negative test results for HIV, Hepatitis B, and Hepatitis C\n\nExclusion Criteria:\n\n* abdominal cancer/surgery within the past 6 months\n* known or suspected immune diseases, e.g. diabetes\n* any chronic or relapsing infections\n* a fever at the time of immunization\n* active vomiting or diarrhea at the time of immunization\n* chronic diarrhea, irritable bowel syndrome, or inflammatory disease of intestinal or colon in the past 12 months\n* subjects' spouses/cohabitants are not healthy or are immunocompromised; roommates in LTCFs are not healthy and/or do not agree to participate in the study\n* cannot be adequately followed for safety via visit or phone\n* any other clinically significant conditions that, in the investigators' opinion, would interfere with subject's participation in the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","maximumAge":"80 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"25424929","type":"RESULT","citation":"Lawrence J, He S, Martin J, Schodel F, Ciarlet M, Murray AV. Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects. Hum Vaccin Immunother. 2014;10(8):2247-54. doi: 10.4161/hv.29107."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Part II was not conducted; no participants were recruited.","recruitmentDetails":"Enrollment of participants occurred at 8 study sites in the United States.","groups":[{"id":"FG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"FG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"22"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Participant who discontinued the study vaccination due to AE completed the 180-day safety follow-up.","numSubjects":"40"},{"groupId":"FG001","numSubjects":"21"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"BG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"66"}]}],"measures":[{"title":"Age, Customized","description":"Between 65 and 80 years.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"66"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"36"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"30"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"66"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part I: Number of Participants With Nonserious and Serious Adverse Experiences (AEs)","description":"All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.","populationDescription":"All randomized participants who received at least one dose of RotaTeq™ or placebo are included in the summaries.\n\nNumber of participants with one or more adverse experience.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Up to 42 days following any dose of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"PRIMARY","title":"Part I: Number of Participants With Serious Adverse Experiences (SAEs)","description":"All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.\n\nSAEs were followed by passive surveillance (in which either participants self reported or information was collected at participants' last visit) for 180 days following the final dose.","populationDescription":"All randomized participants who received at least one dose of RotaTeq™ or placebo are included in the summaries.\n\nNumber of participants with one or more adverse experience.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Up to 180 days following the third dose of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"PRIMARY","title":"Part I: Geometric Mean Titers (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)","description":"GMTs of serum anti-rotavirus IgA responses after 1, 2, or 3 doses of RotaTeq™ or placebo.","populationDescription":"All endpoints exclude protocol violators \\& participants with invalid data based on laboratory determinations.\n\nAnalyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window \\& were not protocol violators.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}]}],"classes":[{"title":"Pre-Vaccination GMT (n=36 RotaTeq/ n=19 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"679.6","lowerLimit":"464.5","upperLimit":"994.2"},{"groupId":"OG001","value":"578.4","lowerLimit":"361.1","upperLimit":"926.4"}]}]},{"title":"Postdose 1 GMT (n=28 RotaTeq/ n=16 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"1026.8","lowerLimit":"621.6","upperLimit":"1696.2"},{"groupId":"OG001","value":"552.8","lowerLimit":"314.5","upperLimit":"971.8"}]}]},{"title":"Postdose 2 GMT (n=37 RotaTeq/ n=20 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"1187.0","lowerLimit":"807.6","upperLimit":"1744.5"},{"groupId":"OG001","value":"657.7","lowerLimit":"404.9","upperLimit":"1068.5"}]}]},{"title":"Postdose 3 GMT (n=38 RotaTeq/ n=18 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"1179.9","lowerLimit":"785.5","upperLimit":"1772.2"},{"groupId":"OG001","value":"578.5","lowerLimit":"349.0","upperLimit":"959.0"}]}]}]},{"type":"PRIMARY","title":"Part II: Number of Participants With Nonserious Adverse Experiences","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","reportingStatus":"POSTED","timeFrame":"Up to 42 days following any dose of RotaTeq™ and/or placebo","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"PRIMARY","title":"Part II: Number of Participants With Serious Adverse Experiences","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","reportingStatus":"POSTED","timeFrame":"Up to 180 days following the third dose of RotaTeq™ and/or placebo","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G1","populationDescription":"All endpoints exclude protocol violators \\& participants with invalid data based on laboratory determinations.\n\nAnalyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window \\& were not protocol violators.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}]}],"classes":[{"title":"Pre-Vaccination GMT (n=36 RotaTeq/ n=19 Placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"314.5","lowerLimit":"219.2","upperLimit":"451.3"},{"groupId":"OG001","value":"281.4","lowerLimit":"152.6","upperLimit":"519.1"}]}]},{"title":"Postdose 1 GMT (n=28 RotaTeq/ n=16 Placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"506.2","lowerLimit":"330.5","upperLimit":"775.4"},{"groupId":"OG001","value":"228.7","lowerLimit":"121.0","upperLimit":"432.4"}]}]},{"title":"Postdose 2 GMT (n=37 RotaTeq/ n=20 Placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"556.1","lowerLimit":"389.8","upperLimit":"793.5"},{"groupId":"OG001","value":"226.7","lowerLimit":"136.8","upperLimit":"375.6"}]}]},{"title":"Postdose 3 GMT (n=38 RotaTeq/ n=18 Placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"535.9","lowerLimit":"395.9","upperLimit":"725.4"},{"groupId":"OG001","value":"231.6","lowerLimit":"140.3","upperLimit":"382.3"}]}]}]},{"type":"SECONDARY","title":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G2","populationDescription":"All endpoints exclude protocol violators \\& participants with invalid data based on laboratory determinations.\n\nAnalyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window \\& were not protocol violators.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}]}],"classes":[{"title":"Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"62.8","lowerLimit":"43.6","upperLimit":"90.5"},{"groupId":"OG001","value":"68.2","lowerLimit":"40.6","upperLimit":"114.6"}]}]},{"title":"Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"123.4","lowerLimit":"81.4","upperLimit":"187.2"},{"groupId":"OG001","value":"56.3","lowerLimit":"34.5","upperLimit":"92.0"}]}]},{"title":"Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"111.2","lowerLimit":"81.6","upperLimit":"151.6"},{"groupId":"OG001","value":"74.3","lowerLimit":"46.2","upperLimit":"119.5"}]}]},{"title":"Postdose 3 GMT (n= 38 RotaTeq/ n=18 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"127.0","lowerLimit":"93.1","upperLimit":"173.3"},{"groupId":"OG001","value":"71.3","lowerLimit":"44.5","upperLimit":"114.3"}]}]}]},{"type":"PRIMARY","title":"Part II: Geometric Mean Titer (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","reportingStatus":"POSTED","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G3","populationDescription":"All endpoints exclude protocol violators \\& participants with invalid data based on laboratory determinations.\n\nAnalyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window \\& were not protocol violators.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}]}],"classes":[{"title":"Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"141.8","lowerLimit":"95.7","upperLimit":"210.1"},{"groupId":"OG001","value":"90.9","lowerLimit":"62.1","upperLimit":"133.0"}]}]},{"title":"Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"404.6","lowerLimit":"230.6","upperLimit":"710.0"},{"groupId":"OG001","value":"94.5","lowerLimit":"59.4","upperLimit":"150.4"}]}]},{"title":"Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"330.7","lowerLimit":"219.5","upperLimit":"498.3"},{"groupId":"OG001","value":"119.8","lowerLimit":"79.6","upperLimit":"180.2"}]}]},{"title":"Postdose 3 GMT (n= 38 RotaTeq/ n=18 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"388.0","lowerLimit":"264.7","upperLimit":"568.7"},{"groupId":"OG001","value":"102.1","lowerLimit":"66.3","upperLimit":"157.3"}]}]}]},{"type":"SECONDARY","title":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G4","populationDescription":"All endpoints exclude protocol violators \\& participants with invalid data based on laboratory determinations.\n\nAnalyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window \\& were not protocol violators.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}]}],"classes":[{"title":"Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"91.6","lowerLimit":"66.1","upperLimit":"126.8"},{"groupId":"OG001","value":"102.7","lowerLimit":"65.7","upperLimit":"160.4"}]}]},{"title":"Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"199.2","lowerLimit":"128.5","upperLimit":"308.6"},{"groupId":"OG001","value":"93.1","lowerLimit":"55.4","upperLimit":"156.2"}]}]},{"title":"Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"223.9","lowerLimit":"154.2","upperLimit":"325.3"},{"groupId":"OG001","value":"110.1","lowerLimit":"68.4","upperLimit":"177.5"}]}]},{"title":"Postdose 3 GMT (n= 3 RotaTeq/ n=18 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"221.7","lowerLimit":"162.9","upperLimit":"301.7"},{"groupId":"OG001","value":"106.9","lowerLimit":"64.2","upperLimit":"178.0"}]}]}]},{"type":"SECONDARY","title":"Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype P1A[8]","populationDescription":"All endpoints exclude protocol violators \\& participants with invalid data based on laboratory determinations.\n\nAnalyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window \\& were not protocol violators.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titers","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo","groups":[{"id":"OG000","title":"RotaTeq","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"22"}]}],"classes":[{"title":"Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"230.8","lowerLimit":"166.8","upperLimit":"319.4"},{"groupId":"OG001","value":"143.4","lowerLimit":"88.9","upperLimit":"231.3"}]}]},{"title":"Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"306.4","lowerLimit":"219.8","upperLimit":"427.0"},{"groupId":"OG001","value":"126.1","lowerLimit":"78.7","upperLimit":"202.0"}]}]},{"title":"Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"375.6","lowerLimit":"278.4","upperLimit":"506.6"},{"groupId":"OG001","value":"154.0","lowerLimit":"98.0","upperLimit":"241.9"}]}]},{"title":"Postdose 3 GMT (n= 38 RotaTeq/ n=18 placebo)","categories":[{"measurements":[{"groupId":"OG000","value":"327.6","lowerLimit":"253.8","upperLimit":"423.0"},{"groupId":"OG001","value":"160.7","lowerLimit":"102.3","upperLimit":"252.3"}]}]}]},{"type":"SECONDARY","title":"Part II: Geometric Mean Titers (GMTs) of Serum Neutralizing Antibody (SNA) Responses to G1, G2, G3, G4, and P1A","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","reportingStatus":"POSTED","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Part II: Percentage of Participants With a >=3-fold Rise From Baseline of Serum Anti-rotavirus IgA and SNA Responses to Rotavirus Serotypes G1, G2, G3, G4 and P1A","description":"Part II was not conducted due to study termination; this report summarizes study results from Part I only.","reportingStatus":"POSTED","timeFrame":"Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3","groups":[{"id":"OG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."},{"id":"OG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"RotaTeq™","description":"Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.","seriousNumAffected":2,"seriousNumAtRisk":44,"otherNumAffected":18,"otherNumAtRisk":44},{"id":"EG001","title":"Placebo","description":"Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.","seriousNumAffected":0,"seriousNumAtRisk":22,"otherNumAffected":4,"otherNumAtRisk":22}],"seriousEvents":[{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Reported within the 43-180 days post vaccination 3","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":44},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":22}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Reported within the 42-day period post vaccination 1","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":44},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":22}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":11,"numAtRisk":44},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":22}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":44},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":22}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":44},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":22}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":44},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":22}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":44},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":22}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":7,"numAtRisk":44},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":22}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.2","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":44},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":22}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Vice President of Late Stage Development","organization":"Merck Sharp & Dohme Corp","email":"ClinicalTrialsDisclosure@merck.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["United States"]}},"hasResults":true}